After hitting highs of Rs110 in mid-January 2014, Dishman Pharma slipped sharply to hit intermediate low of Rs76.
After hitting highs of Rs110 in mid-January 2014, Dishman Pharma slipped sharply to hit intermediate low of Rs76. From there on, the stock has been steadily consolidating. Accumulation between Rs76 - Rs90 range was witnessed during February.
In the process, the stock has formed an inverted head and shoulder (H&S) pattern, which is considered to be bullish. Dishman Pharma broke out of the inverted H&S pattern on March 05, 2014 on the daily chart. The breach has been accompanied with strong up-tick in traded volumes, adding credence to the breakout.
During the consolidation phase, the stock has gradually surpassed key moving averages, and has recently managed to also surge past its 100 Day Moving Average (DMA) as is visible in the daily chart.
Given the intermediate uptrend, the stock is expected to rise post the breach of the 50 DMA, which is placed at Rs92.7. Traditional momentum oscillators are also indicating a positive bias in the counter.
Given the above evidence, we recommend a BUY on Dishman Pharma at current levels for a potential upside target of Rs103. Traders are advised to keep a strict Stop Loss of Rs84.
Aug 09, 2022
Aug 09, 2022
Aug 09, 2022
Aug 09, 2022
Aug 08, 2022
Aug 08, 2022
Aug 08, 2022
Aug 09, 2022
Aug 09, 2022
Aug 09, 2022
Aug 09, 2022
Aug 09, 2022
Aug 09, 2022
Aug 09, 2022
Aug 09, 2022
The laws of the financial world are different from the physical world. You can have prolonged periods of time, when sanity takes a back seat and excesses happen.
R. Venkataraman Aug 20, 2021
Retail trading or day trading has exploded because of falling brokerage rates, democratization of information, higher transparency and mobile platforms.
R. Venkataraman Jun 15, 2021
My simple message for dear readers is, if you don’t have any desperate need for funds, then don’t do anything.
R. Venkataraman May 12, 2021
The blow up of a US hedge fund has resulted in WhatsApp university offering many courses on what went wrong with Bill Hwang and Archegos.
R. Venkataraman Apr 09, 2021
The expensive valuations have been sustained by strong rebound in corporate earnings which led to ~8% upgrade in FY22 Nifty EPS since October 2020.
R. Venkataraman Mar 26, 2021
We believe the interest rates are likely to have bottomed due to inflationary pressure, large government borrowings and normalizing credit growth. Hence rate sensitive sectors should be avoided in our view.
R. Venkataraman Feb 17, 2021
As markets make new highs, one gets more emails and messages, which highlight the accomplishments of traders who have found a formula for making money.
R. Venkataraman Jan 27, 2021
Data does not seem to convincingly prove that short periods of high returns are always followed by meagre returns. Only in 4 instances, we had negative returns in the subsequent year.
R. Venkataraman Jan 01, 2021
Since September end, Bankex is up 16% with large banks like ICICI Bank, Bandhan up 20-27%, Housing Finance Companies like Repco, LICHF, PNB Housing are up 50%-100% from their six-month lows.
R. Venkataraman Oct 13, 2020
Morgan Housel’s 'The Psychology of Money' explains in detail the role of human biases in investment decisions.
R. Venkataraman Sep 26, 2020
Per Order for ETF & Mutual Funds Brokerage
Per Order for Delivery, Intraday, F&O, Currency & Commodity